



REC No	IRAS No	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met	Reasons for not achieving the 70 day benchmark								Source of delay	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start		
							A	B	C	D	E	F	G	H							I	J
							Permissions delayed/denied	Suspended by sponsor	Closed by sponsor	Sponsor Delays	Staff availability issues	No patients seen	No patients consented	Contracting delays							Rare diseases	Other
16/EE/0372	212494	HRA Approval	DETECTION OF METHACHOLINE CHALLENGE INDUCED ASTHMA SYMPTOMS USING A NOVEL DEVICE.			No						Y			Neither	22/12/2016	29/09/2016	06/02/2017		06/02/2017		
16/SC/0494	211989	HRA Approval	A randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome.			No						Y			Neither	18/11/2016	18/01/2017	27/02/2017		27/02/2017		
16/NE/0384	209045	HRA Approval	PARADISE-MI			Within 70 Days										05/01/2017	30/01/2017	07/02/2017		07/02/2017		
16/LO/2078	213487	HRA Approval	Roche RO674281/Trastuzumab/Cetuximab/Obinutuzumab (BP29842)			Within 70 Days										03/02/2017	08/02/2017	09/02/2017		10/02/2017		
16/NE/0236	204005	HRA Approval	Can a commercial activity monitor be used to effectively prescribe exercise and increase physical activity levels in chronic respiratory patients undertaking outpatient pulmonary rehabilitation? ? A feasibility study		13/12/2016	Yes	Y				Y				Neither	11/10/2016	10/11/2016	10/11/2016		10/11/2016		
16/EM/0165	203281	HRA Approval	A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib		06/09/2016	Yes										12/07/2016	28/07/2016	05/08/2016		05/08/2016		
16/EM/0461	213043	HRA Approval	Improving identification of familial hypercholesterolaemia in primary care (FAMCAT)			Within 70 Days										03/02/2017	26/10/2016	23/02/2017		23/02/2017		
16/EM/0482	216043	HRA Approval	Participant Acceptability of Exercise in Kidney Disease		15/03/2017	Yes										27/01/2017	02/03/2017	02/03/2017		02/03/2017		
16/LO/1822	212944	HRA Approval	CARD 5650			Within 70 Days										07/12/2016	07/02/2017	08/03/2017		08/03/2017		
16/EM/0500	213455	HRA Approval	Indapamide treatment for heart failure - a pilot study			No	Y								Neither	14/02/2017	08/03/2017	08/03/2017		08/03/2017		
16/EE/0463	214371	HRA Approval	CompLEment-1			Within 70 Days										30/01/2017	07/03/2017	17/03/2017		17/03/2017		
16/WM/0118	182909	HRA Approval	SENTIMAG (Smart)			Within 70 Days										05/07/2016	28/03/2017	21/03/2017		21/03/2017		
17/EM/0014	219556	HRA Approval	PRO-100-0145 - TissuGlu Mastectomy		30/03/2017	Yes										10/03/2017	14/03/2017	21/03/2017		21/03/2017		
16/WM/0472	211270	HRA Approval	CONFIRM			Within 70 Days										14/03/2017	20/03/2017	28/03/2017		28/03/2017		
16/NW/0517	188554	HRA Approval	Myeloma XII (ACCoRd trial) Version 1.0			Within 70 Days										27/10/2016	06/04/2017	28/03/2017		29/03/2017		
16/WM/0473	213847	HRA Approval	CA209-817 - Nivolumab and Ipilimumab in advanced malignancies			Within 70 Days										02/03/2017	23/03/2017	28/03/2017		29/03/2017		
16/EM/0488	210608	HRA Approval	Baby Steps - Walking away from Gestational Diabetes			Within 70 Days										01/03/2017	31/03/2017	31/03/2017		31/03/2017		